Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease

Cheng MA; Hui YANG

doi:10.3969/j.issn.1001-5256.2023.07.028

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1708-1713

PDF( 2315 KB)

Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.07.028

Cheng MA¹,
Hui YANG^{2
,
,
,}

1.
Graduate School of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Infectious Diseases, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Scientific Research Project of Shanxi Province Raises Funds to Support Overseas Students (2020-168)

More Information

Corresponding author: YANG Hui, 576371816@qq.com (ORCID: 0000-0002-9162-6951)
Received Date: 2022-09-20
Accepted Date: 2022-11-21
Published Date: 2023-07-20

Abstract

Abstract

The incidence rate of alcoholic liver disease (ALD) is increasing year by year China, and there is a gradual increase in disease burden among Chinese people. Oxidative stress response in hepatocytes is an important pathogenic mechanism of ALD. The nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway is an important endogenous anti-oxidative stress pathway in the body, and Nrf2 is activated in response to oxidative stress and exerts its transcriptional activity to induce high HO-1 expression. HO-1 is an important oxidative stress response protein and plays a role in anti-inflammation, anti- oxidation, and cell apoptosis regulation together with heme hydrolysis products (bilirubin, carbon monoxide, and iron). This article reviews the research advances in the role of the Nrf2/HO-1 signaling pathway in ALD in recent years, so as to find a theoretical basis for the development and progression of ALD and an entry point for treatment.
- Liver Diseases, Alcoholic,
- NF-E2-Related Factor 2,
- Heme Oxygenase-1,
- Signal Transduction

FullText(HTML)

References(36)

References

[1]	Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006. 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
[2]	SILVA-ISLAS CA, MALDONADO PD. Canonical and non-canonical mechanisms of Nrf2 activation[J]. Pharmacol Res, 2018, 134: 92-99. DOI: 10.1016/j.phrs.2018.06.013.
[3]	SHAW P, CHATTOPADHYAY A. Nrf2-ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms[J]. J Cell Physiol, 2020, 235(4): 3119-3130. DOI: 10.1002/jcp.29219.
[4]	ZHANG A, SUZUKI T, ADACHI S, et al. Distinct regulations of HO-1 gene expression for stress response and substrate induction[J]. Mol Cell Biol, 2021, 41(11): e0023621. DOI: 10.1128/MCB.00236-21.
[5]	RYTER SW. Heme oxygenase-1: An anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders[J]. Antioxidants (Basel), 2022, 11(3): 555. DOI: 10.3390/antiox11030555.
[6]	ZHOU J, ZHENG Q, CHEN Z. The Nrf2 pathway in liver diseases[J]. Front Cell Dev Biol, 2022, 10: 826204. DOI: 10.3389/fcell.2022.826204.
[7]	SHERIFF L, KHAN RS, SABORANO R, et al. Alcoholic hepatitis and metabolic disturbance in female mice: a more tractable model than Nrf2^-/- animals[J]. Dis Model Mech, 2020, 13(12): dmm046383. DOI: 10.1242/dmm.046383.
[8]	WANG G, FU Y, LI J, et al. Aqueous extract of Polygonatum sibiricum ameliorates ethanol-induced mice liver injury via regulation of the Nrf2/ARE pathway[J]. J Food Biochem, 2021, 45(1): e13537. DOI: 10.1111/jfbc.13537.
[9]	WANG X, CHANG X, ZHAN H, et al. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway[J]. J Food Biochem, 2020. DOI: 10.1111/jfbc.13425.[Online ahead of print]
[10]	FERDOUSE A, CLUGSTON RD. Pathogenesis of alcohol-associated fatty liver: lessons from transgenic mice[J]. Front Physiol, 2022, 13: 940974. DOI: 10.3389/fphys.2022.940974.
[11]	OSNA NA, DONOHUE TM Jr, KHARBANDA KK. Alcoholic liver disease: pathogenesis and current management[J]. Alcohol Res, 2017, 38(2): 147-161.
[12]	SEEN S. Chronic liver disease and oxidative stress - a narrative review[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(9): 1021-1035. DOI: 10.1080/17474124.2021.1949289.
[13]	CHEN WY, SHU FM, WANG H, et al. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. J Chin Hepatol, 2022, 38(9): 2182-2187. DOI: 10.3969/j.issn.1001-5256.2022.09.045. 陈玮钰, 舒发明, 王涵, 等. 细胞色素P450家族在肝脏代谢相关疾病中的作用[J]. 临床肝胆病杂志, 2022, 38(9): 2182-2187. DOI: 10.3969/j.issn.1001-5256.2022.09.045.
[14]	WU KC, LIU J, KLAASSEN CD. Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation[J]. Toxicol Appl Pharmacol, 2012, 262(3): 321-329. DOI: 10.1016/j.taap.2012.05.010.
[15]	PALIPOCH S, KOOMHIN P, PUNSAWAD C, et al. Heme oxygenase-1 alleviates alcoholic liver steatosis: histopathological study[J]. J Toxicol Pathol, 2016, 29(1): 7-15. DOI: 10.1293/tox.2015-0035.
[16]	BUKO V, ZAVODNIK I, BUDRYN G, et al. Chlorogenic acid protects against advanced alcoholic steatohepatitis in rats via modulation of redox homeostasis, inflammation, and lipogenesis[J]. Nutrients, 2021, 13(11). DOI: 10.3390/nu13114155.
[17]	TOROK NJ. Update on alcoholic hepatitis[J]. Biomolecules, 2015, 5(4): 2978-2986. DOI: 10.3390/biom5042978.
[18]	HOSSEINI N, SHOR J, SZABO G. Alcoholic hepatitis: a review[J]. Alcohol Alcohol, 2019, 54(4): 408-416. DOI: 10.1093/alcalc/agz036.
[19]	RAMOS-TOVAR E, MURIEL P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage[J]. J Appl Toxicol, 2020, 40(1): 151-168. DOI: 10.1002/jat.3880.
[20]	GALICIA-MORENO M, LUCANO-LANDEROS S, MONROY-RAMIREZ HC, et al. Roles of Nrf2 in liver diseases: molecular, pharmacological, and epigenetic aspects[J]. Antioxidants (Basel), 2020, 9(10): 980. DOI: 10.3390/antiox9100980.
[21]	HONG DG, SONG GY, EOM CB, et al. Loss of ERdj5 exacerbates oxidative stress in mice with alcoholic liver disease via suppressing Nrf2[J]. Free Radic Biol Med, 2022, 184: 42-52. DOI: 10.1016/j.freeradbiomed.2022.03.027.
[22]	RYTER SW. Heme oxgenase-1, a cardinal modulator of regulated cell death and inflammation[J]. Cells, 2021, 10(3): 515. DOI: 10.3390/cells10030515.
[23]	LIU S, TIAN L, CHAI G, et al. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation[J]. Food Funct, 2018, 9(8): 4184-4193. DOI: 10.1039/c8fo00650d.
[24]	ZHANG Y, WU Y, SHEN W, et al. Crosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review)[J]. Mol Med Rep, 2022, 25(6): 208. DOI: 10.3892/mmr.2022.12724.
[25]	LI T, LIU HB, HU WY, et al. Role of inflammation in hepatic fibrosis[J]. J Clin Hepatol, 2022, 38(10): 2368-2372. DOI: 10.3969/j.issn.1001-5256.2022.10.032. 李婷, 刘华宝, 胡文艳, 等. 炎症在肝纤维化中的作用[J]. 临床肝胆病杂志, 2022, 38(10): 2368-2372. DOI: 10.3969/j.issn.1001-5256.2022.10.032.
[26]	CHENG ML, LU YF, CHEN H, et al. Liver expression of Nrf2-related genes in different liver diseases[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(5): 485-491. DOI: 10.1016/s1499-3872(15)60425-8.
[27]	NUNES DOS SANTOS K, FLORENTINO RM, FRANÇA A, et al. Polymorphism in the promoter region of NFE2L2 gene is a genetic marker of susceptibility to cirrhosis associated with alcohol abuse[J]. Int J Mol Sci, 2019, 20(14): 3589. DOI: 10.3390/ijms20143589.
[28]	NI YH, HUO LJ, LI TT. Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22[J]. World J Gastroenterol, 2017, 23(11): 2002-2011. DOI: 10.3748/wjg.v23.i11.2002.
[29]	LIU Y, KUANG Q, DAI X, et al. Deficiency in inactive rhomboid protein2 (iRhom2) alleviates alcoholic liver fibrosis by suppressing inflammation and oxidative stress[J]. Int J Mol Sci, 2022, 23(14): 7701. DOI: 10.3390/ijms23147701.
[30]	YANG H, ZHANG L, CHEN J, et al. Heme oxygenase-1 inhibits the proliferation of hepatic stellate cells by activating PPARγ and suppressing NF-κB[J]. Comput Math Methods Med, 2022, 2022: 8920861. DOI: 10.1155/2022/8920861.
[31]	BUCHANAN R, SINCLAIR J. Alcohol use disorder and the liver[J]. Addiction, 2021, 116(5): 1270-1278. DOI: 10.1111/add.15204.
[32]	GANNE-CARRIÉ N, NAHON P. Hepatocellular carcinoma in the setting of alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 284-293. DOI: 10.1016/j.jhep.2018.10.008.
[33]	ZHANG C, LI L, HOU S, et al. Astragaloside Ⅳ inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways[J]. J Ethnopharmacol, 2021, 279: 114350. DOI: 10.1016/j.jep.2021.114350.
[34]	ZOU C, ZOU C, CHENG W, et al. Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway[J]. Oncol Rep, 2016, 36(5): 2715-2722. DOI: 10.3892/or.2016.5056.
[35]	RAGHUNATH A, SUNDARRAJ K, ARFUSO F, et al. Dysregulation of Nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance[J]. Cancers (Basel), 2018, 10(12): 481. DOI: 10.3390/cancers10120481.
[36]	WU MM, HSIEH FI, HSU LI, et al. GT-repeat polymorphism in the HO-1 gene promoter Is associated with risk of liver cancer: a follow-up study from arseniasis-endemic areas in Taiwan[J]. J Clin Med, 2021, 10(7): 1489. DOI: 10.3390/jcm10071489.

Relative Articles

[1]	Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
[2]	Haimei GUAN, Kan ZHANG, Weiyu CHEN, Guobao LI, Yangling ZENG, Riyun ZHANG, Tianwen WANG, Baohua XIE, Dewen MAO. Mechanism of action and potential value of the IRE1α/TRAF2/JNK pathway in the progression of acute liver failure[J]. Journal of Clinical Hepatology, 2024, 40(6): 1281-1288. doi: 10.12449/JCH240633
[3]	Xin ZHOU, Zhi WANG, Xueru HE, Yuhao FU, Xuejiao XUN, Ying LI, Zhanjun DONG. Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets[J]. Journal of Clinical Hepatology, 2023, 39(12): 2932-2941. doi: 10.3969/j.issn.1001-5256.2023.12.027
[4]	Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
[5]	Yi CHEN, Yifan CHEN, Yichao DU, Peng TAN, Tongxi LI, Junjie BAI, Wenguang FU. Effect and mechanism of safranal in a mouse model of sepsis-related liver injury induced by lipopolysaccharide[J]. Journal of Clinical Hepatology, 2023, 39(11): 2643-2650. doi: 10.3969/j.issn.1001-5256.2023.11.019
[6]	Ming WANG, Jianhu XU, Li MA. Mechanism of action of Dange Jiecheng decoction in a rat model of alcoholic liver disease based on the Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(5): 1119-1125. doi: 10.3969/j.issn.1001-5256.2023.05.018
[7]	Shudi LI, Xinju CHEN, Jiangkai LIU, Zhen WANG, Fei DUAN, Zhuoya YUAN, Lei LIANG, Suling LI. Signaling pathways involved in the active components of Polygonum cuspidatum in treatment of nonalcoholic fatty liver disease and their interaction[J]. Journal of Clinical Hepatology, 2022, 38(4): 902-907. doi: 10.3969/j.issn.1001-5256.2022.04.033
[8]	Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
[9]	Yannan XU, Ping LIU, Yongping MU. Effects of different subtypes of Numb protein subtypes on liver fibrosis-related signaling pathways[J]. Journal of Clinical Hepatology, 2021, 37(1): 169-172. doi: 10.3969/j.issn.1001-5256.2021.01.036
[10]	Jingxia HE, Xiuqin AN, Jinchun LIU. Research advances in autophagy-related signal molecules in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2220-2224. doi: 10.3969/j.issn.1001-5256.2021.09.044
[11]	Hui QUAN, Yuyong JIANG. Role of interleukin-1β in the pathogenesis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2021, 37(5): 1226-1228. doi: 10.3969/j.issn.1001-5256.2021.05.053
[12]	Yujuan PENG, Jing YOU, Jing LI, Guangjun TANG. Role of the JAK/STAT/SOCS signaling pathway in hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1435-1439. doi: 10.3969/j.issn.1001-5256.2021.06.045
[13]	Deng YangYang, Ge ShanFei, Yu YanQing, Xiong Ying. Cell signaling pathways associated with liver fibrosis and potential therapeutic strategies[J]. Journal of Clinical Hepatology, 2020, 36(5): 1141-1145. doi: 10.3969/j.issn.1001-5256.2020.05.043
[14]	HUANG Qing, LI JingTao, LIU YongGang, WEI HaiLiang, YAN ShuGuang, GUO YingJun, CHANG ZhanJie. Regulatory effect of mTOR pathway-mediated autophagy in liver injury[J]. Journal of Clinical Hepatology, 2020, 36(11): 2621-2625. doi: 10.3969/j.issn.1001-5256.2020.11.051
[15]	Lu XiaoLiang, Jiang YuanYe, Cao Qin. The role of oxidative stress and nuclear factor erythroid 2-related factor 2 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 924-927. doi: 10.3969/j.issn.1001-5256.2020.04.048
[16]	He GuoNa, Shen FengJun. Association between nuclear factor-erythroid 2-related factor-2 antioxidant pathway and liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(4): 930-933. doi: 10.3969/j.issn.1001-5256.2019.04.050
[17]	Peng Qin, Zhao ShenJun, Li Wu. Research advances in signaling pathways involved in the development of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(5): 954-958. doi: 10.3969/j.issn.1001-5256.2017.05.035
[18]	Wang WeiHao, Xu WeiHua. Roles of Nrf2 and autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 447-451. doi: 10.3969/j.issn.1001-5256.2015.03.033
[19]	Nan YueMin, Mi HongMei, Du JingHua, Wang RongQi, Kong LingBo, Ren WeiGuang, Li Hui, Zhao SuXian. Role and molecular mechanism of HO-1-mediated NF-κB modulation in fibrosis progression of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2013, 29(5): 375-378.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	曹丹，陈祺，陈小橹，陈林珍，王海燕，郝巨辉，张威，马志强. 基于Nrf2/HO-1信号通路探讨四逆散对胆汁淤积性肝炎大鼠氧化应激反应的影响. 中国实验方剂学杂志. 2024(12): 1-7 .
2.	平烨，张珮雯，袁馨梦，项梦奇，杨梦凡，林小霞，董诗茹，刘宇婷，张媛. 运动调节Nrf2/HO-1通路改善HFFC膳食诱导肝细胞氧化应激的作用研究. 中国实验动物学报. 2024(05): 566-575 .
3.	黄志远，邹蕾，李娇，崔婷婷. 急性药物性肝损伤患者血清核因子E_2相关因子2、血红素加氧酶-1、脂肪酸结合蛋白4、缺氧诱导因子1α表达意义及其与肝功能指标相关性研究. 陕西医学杂志. 2024(07): 983-986 .
4.	罗美美，朱星宇，胡乐涛，吴育，李伟东. 基于Nrf2/HO-1信号通路的中药有效成分缓解肝损伤研究进展. 药物评价研究. 2024(07): 1638-1644 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (758) PDF downloads(80)

Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.07.028

Abstract

References

Relative Articles

Cited by

Periodical cited type(4)

Other cited types(4)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content